The Avalere study did not evaluate if Medicare drug coverage has translated into improved health for seniors with Medicare drug coverage. According to Barton, this type of research is currently not feasible.
"Regrettably, outcomes research on the Medicare population post-Part D implementation is hindered by the lack of integrated data from Medicare Part A, B, and D. Policymakers should consider the value of this type of integrated medical and pharmacy claims dataset and work fast to make it available to enable a deeper evaluation of Part D's success or shortcomings."
Avalere used its proprietary DataFrame database of Part D plan benefit and formulary designs to characterize access to diabetes-related drugs in Part D and Wolters Kluwer's Source Lx, a nationally representative claims data repository, to analyze drug utilization and out-of-pocket costs from January 1, 2004 through September 30, 2007.
"The Impact of Medicare Part D on Beneficiaries with Type 2 Diabetes: Drug Utilization and Out-of-Pocket Expenses," was authored by Zeynal Karaca, Sonya B. Streeter, Valerie Barton, Khoa Nguyen, and Kris Norris, all of Avalere Health. Takeda Pharmaceuticals North America provided funding for the research. Avalere maintained editorial control and the conclusions expressed in the research paper are solely those of the authors.
| SOURCE Avalere Health Copyright©2008 PR Newswire. All rights reserved |